Charcot-Marie-Tooth Disease
A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)
Drugs by status
Phase 4 trials (1)
Phase 2 trials (11)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (17)
- INC Research
- Ortho Biotech, Inc.
- Pharnext SA
- Muscular Dystrophy Association
- Katholieke Universiteit Leuven
- University of Manchester
- University of Toronto
- University of Alberta
- Wayne State University
- St. Louis University
- University of Munster
- Seton Hall University
- University of Amsterdam
- Salford Royal Foundation NHS Trust
- Aix-University of Marseille
- Synteract, Inc.
- Charcot-Marie-Tooth Association
Organization Involved with Phase 2 Indications (10)
Organization Involved with Other Experimental Indications (1)